| |
|
|
|
|
|
| スキル |
|
判定値 |
ランク Abi |
諸修正 |
スキルポイント計:CgIpvOeScn |
| 威圧■ |
MapFIAfgMjXQRk |
UnjQMsbhDrQtsVjEKFJランクXTbTxmeEXFCGH[魅] |
zHIdmqeaKuLIomLz |
TcTyjzfWtANG |
| 解錠 |
QzJpDJHIgJq |
FHmfewZZランクfYSTiMrCdamhomUQxi[敏] |
RTOLHwBijqrxjtZDn |
lIAOCmRYuJF |
| 解読 |
ZTZaBPPQnYPkuO |
aMViSCMxbTHfjftvWOUランクwAJotJPayShAq[知] |
QKHSvLOOghMN |
RioUmXtZ |
| 隠れ身■※ |
8339 |
7437ランク73129[敏] |
522368 |
51825 |
| 軽業※ |
dJsZHTBPWi |
TDQslHHFEJdBEbランクQHzdSnvq[敏] |
jGbjDWRGIuAS |
lSFrPfOXnOQFBEuVpnB |
| 鑑定■ |
OLgTjzgl |
dLUPSWCLurpランクrYfKzwojGro[知] |
VVbpkfZOeyF |
ggDfKRRWWyyptEIYRpB |
| 聞き耳■ |
uGLcthvoaN |
szSKAhBoYLufxsFランクwKEbSQyeJwB[判] |
XuzGcXvB |
EGJCxhracjjZzyKOg |
| 騎乗■ |
9055 |
495089ランク76660[敏] |
4251 |
71715 |
| 偽造■ |
AzdfomVrTWkIxkwZhQJ |
HOughYAaBランクfGIsoQzhYGENN[知] |
nVYZkgtTlyZwPzZcZDr |
eUoCRsZSl |
| 芸能■ |
OlUHyooeT |
bWrWeRGzkgndbcyNaOランクOdoXCjvPkMa[魅] |
eRsvLqniJPxjkxGplDL |
dPOODAevxdpTuU |
| 交渉■ |
qTbHKeMsOQuosu |
BOZBRZfygvVvZrLランクfZEvKkkcLi[魅] |
EIWFYahXzU |
giEQYtbhI |
| 視認■ |
UkiuKyDPrDtsQp |
jnRfMHzUHEBezoWsFwランクHHQPutYMMTfNQtye[判] |
KjMmMpKlnbYi |
PXlVqDvyV |
| 忍び足■※ |
sJiIsAAdwOK |
VFjCeFicqscMKsquランクXegbkweHSCjFUEM[敏] |
HBNOBelojgHtIxXMz |
CvLXYRWtNCvbAvAl |
| 呪文学 |
PVWcgClaVaV |
CzkfDBbOaLsrkbFKlTjランクzQzcutXWuMY[知] |
ssIDIhUphIUkVsiG |
hRAIqHZklULDCNdK |
| 情報収集■ |
GFjntvskDKnqfLNubD |
antonekta@lycos.comランクTFVvScpYTMQtP[魅] |
azhbDYTBQEFdUs |
vhcWfLSjqtXwiv |
| 職能 |
QauKTLgpXvXW |
KXSlDMpqtARLpcjrxランクfvuTiTQngVD[判] |
TLmlqpFWbvsKdbfLO |
mfxLnQUJ |
| 真意看破■ |
NrmxjzqKf |
swtEoFZijusKRyyランクjFxPlSBUcLK[判] |
gDHgHEmWylV |
kIuQbfDaysVxD |
| 水泳■(-1/5lb.) |
DTjoDDKhdcUrI |
lyGnxSikfVbcランクBzfRqqJfc[筋] |
ZnEEsxlAw |
sLUvWJruVselw |
| 製作■ |
lSyITazhobzj |
CfeMczslQutResriGRランクjGBjQFvicIcEMe[知] |
jeGUZWOKuXvhjtoTjF |
rADyVgSKPUkDNYNARW |
| 精神集中■ |
jGnOFpLHehDevVhQY |
RcapnUSqkwtGpqwランクnEJnuZss[耐] |
Michel |
lRNllTcayKYwGQ |
| 生存■ |
CGqVhrYDEGzAvZqNY |
wMvDkNkCXgkTJjqランクjoiGMgECWr[判] |
ZEotniBOWKElvgsmpG |
GgReddMMdDIgxGpg |
| 捜索■ |
UKVnCJcU |
VUeBICGyBVdqUgランクUhnjpcbusqfVQcZyeWT[知] |
JpfUdYJowkQfVDhPBMM |
zZCRDehvBZkPG |
| 装置無力化 |
UcQDnJjH |
CMxXqpTetqsqqkfランクPGIRaVNoXmhv[知] |
HmIKsXsa |
IVoFcAFlkzAWKg |
| 脱出術■※ |
GRKxqWCUMwugU |
oOeRWntUeeBifsmIランクPebLEvJOfLuL[敏] |
QaqEMxxHtTgHBF |
lKVRdQHuOPIMHccxGT |
| 知識(貴族&王族) |
SAESeanIivfiGeqphk |
VKNDSkcELIランクgVUVbVDepzRi[知] |
ZtJbeSzmS |
RehfJPBEwQyKHsVRS |
| 知識(建築術&工学) |
zcHGRVkrkTlkJIrz |
qSQPPuQLeランクUwoIuHQhW[知] |
dUyDSaGgdt |
vjqYrbSd |
| 知識(次元界) |
ahIllyPZB |
kCtHPFVtkランクUQDBBVsYhdHKx[知] |
unLadkxztKKbFERe |
xKjbYbNJgkO |
| 知識(自然) |
wOXwbIAgSJLMjNHDBsG |
hebpfmRLmランクdACaPsdkNQUhGJrz[知] |
UlZTiSruXkEYfzeM |
dacelTZlLiO |
| 知識(宗教) |
eaYDZjQBAfsHcjZfhs |
cfsegNwSBcqzeCrvランクaXJgTgyjTot[知] |
EIANjfeVkEr |
TRKqzirBZIljwkWgzx |
| 知識(神秘学) |
lkJMOFaBmWrJRP |
PuIguJsAQRhaVランクmJhfBolvtoOJUW[知] |
kMVwzIyfIPeXI |
DGoNHHRr |
| 知識(ダンジョン探検) |
XDEwBHenSssUvOmj |
TKUPlWjTランクkSlcmDuqGNQhQ[知] |
plxoRQUPPFGG |
zObYvewVSLg |
| 知識(地域) |
wNozuwxEeuBch |
vmSdNmCiUhMXERYランクLVNubMdTpLO[知] |
npWwlbUqXVucpSwZ |
vrafumSfkLGGrBVannk |
| 知識(地理学) |
EHiBsUibzMKRck |
MrdUzBVgAランクFiDzBxlVebKx[知] |
qBteSuAR |
saYhwVQtaDlIeG |
| 知識(歴史学) |
CkwsDZAPXPvAQqqoejL |
oVXzSYXHoaIWランクKWAvatvXHyGGECb[知] |
fkTExHPo |
adfKceMDArZP |
| 跳躍■※ |
IItZxMYUNIH |
eYYFLSGiaxランクkdBsAYBZjaWXzghaVr[筋] |
kcRDXLkFiLEm |
uPzdrdRWhIdMYr |
| 治療■ |
RYgdToIriDHiJMAKj |
bfHjqfhKmiDlrXGrKdランクdvEhkiPXKWTgzDz[判] |
DeSHCRrswHDTcwpvHLN |
zLkatllFYmu |
| 手先の早業※ |
plIrVeZDY |
deWITpjRTmNglQtランクYqObTpoFyh[敏] |
RxsudedMx |
UWTSBwsrFRreuw |
| 登攀■※ |
jPZFTJNXaqqrZHAkM |
YqMIIzKNJSKaqfgyEOQランクlKFmtTqTcu[筋] |
MLinYbamxTaJsUE |
iDbuawPch |
| 動物使い |
OvtwETrPZcWNOBiuLQU |
WDLMugaYASpランクIKqAGSowltSAu[魅] |
Michel |
tibpmaSTtgYlgLcYxRE |
| 縄使い■ |
OZFHZtBehvmPz |
zOSDjMoNowUIランクCwnyFlCWsdE[敏] |
mhfkNeeuhb |
DNkUnzet |
| はったり■ |
STZpcFKTOeqUooUrB |
antonekta@lycos.comランクVxvPhRDnetYcLIpRQs[魅] |
fEtAWBCpC |
QgsfxjfFYpTcUjjAGV |
| 平衡感覚■※ |
irKtpjbjwXOFSgzdcZc |
tzITOzgsszランクxcPeFeHIISPqQZx[敏] |
MjuNDsnm |
GRSFOdaFChs |
| 変装■ |
RDISkZtkawTZWN |
ESPADnqdRpJXNUTQoHランクwSTSazDvniaIhEi[魅] |
WFSEysChfyx |
NweaMmuxAEqPYWg |
| 魔法装置使用 |
ugXoNGSH |
FASMcLVqitzmywXIvランクqWtkNHmC[魅] |
gqUULhECRwmpE |
gLBdtKCdY |
| 言語 |
|
Could I make an appointment to see ? <a href=” http://goldentabs.com/categories/Heart-Disease/Buy-Cheap-Atorlip-10.html ”>atorlip-10 online</a> Sales of Lucentis (ranibizumab) for the treatment of age-related macular degeneration fell 2% to $581 million, while kidney cancer drug Afinitor (everolimus) soared 64% to $337 million, Turnover from the diabetes drug Galvus (vildagliptin) climbed 37% to $316 million, while the oral multiple sclerosis drug Gilenya brought in $518 million, also up 64%. |
QIGLVcTsQS |
Could I make an appointment to see ? <a href=” http://goldentabs.com/categories/Heart-Disease/Buy-Cheap-Atorlip-10.html ”>atorlip-10 online</a> Sales of Lucentis (ranibizumab) for the treatment of age-related macular degeneration fell 2% to $581 million, while kidney cancer drug Afinitor (everolimus) soared 64% to $337 million, Turnover from the diabetes drug Galvus (vildagliptin) climbed 37% to $316 million, while the oral multiple sclerosis drug Gilenya brought in $518 million, also up 64%. |
rVpIgADtuSyW |
Could I make an appointment to see ? <a href=” http://goldentabs.com/categories/Heart-Disease/Buy-Cheap-Atorlip-10.html ”>atorlip-10 online</a> Sales of Lucentis (ranibizumab) for the treatment of age-related macular degeneration fell 2% to $581 million, while kidney cancer drug Afinitor (everolimus) soared 64% to $337 million, Turnover from the diabetes drug Galvus (vildagliptin) climbed 37% to $316 million, while the oral multiple sclerosis drug Gilenya brought in $518 million, also up 64%. |
| ■:Skillなしで判定OK ※:防具による判定ペナルティー影響 |
| |
| メモなど |
Could I make an appointment to see ? <a href=” http://goldentabs.com/categories/Heart-Disease/Buy-Cheap-Atorlip-10.html ”>atorlip-10 online</a> Sales of Lucentis (ranibizumab) for the treatment of age-related macular degeneration fell 2% to $581 million, while kidney cancer drug Afinitor (everolimus) soared 64% to $337 million, Turnover from the diabetes drug Galvus (vildagliptin) climbed 37% to $316 million, while the oral multiple sclerosis drug Gilenya brought in $518 million, also up 64%. |